Fibrosing interstitial lung disease (F-ILD) is a group of chronic, progressive conditions characterized by the permanent scarring of lung tissue, which leads to a gradual decline in respiratory function. Approximately one-third of individuals diagnosed with F-ILD will follow a progressive fibrosing phenotype, a clinical course associated with significant mortality and a high socioeconomic burden. Early identification of these patients is critical for timely intervention, yet current clinical monitoring tools—such as pulmonary function tests and high-resolution computed tomography (HRCT)—often fail to capture biological fibrotic activity until structural damage has already occurred.
At Groundwork, our analysis of emerging diagnostic frameworks indicates that molecular imaging targeting fibroblast activation protein (FAP) represents a significant shift in how we monitor lung fibrosis. By utilizing 99mTc-FAPI SPECT/CT, clinicians may soon be able to visualize and quantify active fibrotic processes at the pathological level before they manifest as irreversible lung volume loss.
99mTc-FAPI SPECT/CT is a diagnostic imaging technique that uses a radioactive tracer to bind specifically to fibroblast activation protein (FAP), a marker highly expressed by activated fibroblasts in areas of active tissue remodeling and fibrosis. Unlike traditional imaging, which primarily detects structural changes, this molecular imaging approach identifies the biological drivers of the disease process.
In the context of F-ILD, fibroblasts are the primary cells responsible for the excessive deposition of extracellular matrix, which leads to the stiffening of lung tissue. According to recent study protocols registered with the Chinese Clinical Trial Registry (ChiCTR2400093808), the goal of integrating FAPI imaging into clinical practice is to provide an 'early warning' system for disease progression. By quantifying the uptake of the FAPI tracer in the lungs, clinicians can theoretically distinguish between stable fibrotic disease and active, rapidly progressing tissue injury. This distinction is vital because patients with highly active fibrotic processes may require more aggressive or earlier initiation of antifibrotic therapies.
Traditional monitoring for F-ILD relies heavily on serial pulmonary function testing (PFT) and HRCT scans. A PFT measures how much air you can inhale and exhale, as well as how efficiently oxygen is transferred into your blood. HRCT provides high-resolution images of the lung architecture. While these tools remain the standard of care, they possess significant limitations in sensitivity.
- Lag time: PFT and HRCT findings often lag behind the underlying biological activity. By the time a decline in forced vital capacity (FVC) is detected, the disease may have already caused substantial, permanent loss of lung function.
- Sensitivity: HRCT is excellent at showing the 'scars' of the disease but is less effective at identifying the metabolic 'engine' driving the scar formation.
- Variability: PFT results can be influenced by patient effort and external factors, making it difficult to distinguish between acute fluctuations and true disease progression.
Groundwork’s synthesis of clinical data suggests that molecular imaging fills these diagnostic gaps by providing a real-time metabolic snapshot of the lung, allowing for more proactive rather than reactive clinical management.
Keep exploring
More from GroundworkTo validate the predictive power of 99mTc-FAPI SPECT/CT, a prospective, single-centre study is currently underway, recruiting 380 patients with confirmed F-ILD. The study design is built around a 12-month follow-up period to correlate baseline FAPI imaging results with objective clinical outcomes. The primary outcome measure—defined as disease progression—utilizes a multi-faceted clinical definition:
- A decline in forced vital capacity (FVC) of ≥5%.
- A decline in the diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥10%.
- Radiological evidence of increased fibrosis on follow-up HRCT scans.
- The occurrence of acute exacerbations of the underlying lung disease.
- All-cause mortality.
By comparing the FAPI uptake values (quantitative parameters) at the baseline to these clinical outcomes, researchers intend to build a predictive model. This model will integrate imaging data with standard clinical variables, such as the 6-minute walk test and laboratory biomarkers, to calculate an individual's risk score for rapid progression.
Predictive modeling in F-ILD aims to move away from a 'one-size-fits-all' approach to treatment. If an imaging-based model can accurately categorize a patient as 'high-risk' for progression, it provides a data-driven justification for initiating specialized antifibrotic treatments earlier in the disease course.
Internal validation of this model will occur via bootstrap resampling and temporal split methods, ensuring that the findings are robust and not merely artifacts of a specific patient group. At Groundwork, we emphasize that for such models to be clinically useful, they must demonstrate high negative predictive value—meaning that if the FAPI scan is low, the patient is highly likely to remain stable. This would allow clinicians to avoid unnecessary, potentially toxic treatments for patients who are not at immediate risk of rapid decline.
If you are living with F-ILD, it is important to understand that current research is moving toward personalized, biomarker-driven care. While 99mTc-FAPI SPECT/CT is currently in the investigation phase, it represents a promising frontier in lung disease management.
- Discuss your current monitoring schedule with your pulmonologist, ensuring you are receiving regular PFTs and HRCTs.
- Inquire about clinical trials if you are interested in accessing novel diagnostic or therapeutic interventions.
- Maintain a comprehensive record of your symptoms, including changes in breathlessness during exertion, as these subjective reports are essential for your medical team to interpret alongside objective test results.
